Information Provided By: 
Fly News Breaks for February 8, 2019
LGND
Feb 8, 2019 | 07:34 EDT
H.C. Wainwright analyst Joseph Pantginis says the 2018 results posted by Ligand Pharmaceuticals "speak for themselves." The company's two core royalty bearing assets, Promacta and Kyprolis, are continuing to generate significant revenues, Pantginis tells investors in a post-earnings research note. He also believes the Vernalis acquisition "looks promising." The analyst reiterates a Buy rating on Ligand with a $281 price target.
News For LGND From the Last 2 Days
There are no results for your query LGND
